LMR Partners LLP Purchases New Shares in Insulet Co. (NASDAQ:PODD)

LMR Partners LLP acquired a new stake in Insulet Co. (NASDAQ:PODD - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 15,111 shares of the medical instruments supplier's stock, valued at approximately $3,517,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of PODD. QRG Capital Management Inc. acquired a new stake in shares of Insulet during the 3rd quarter valued at approximately $297,000. Diversified Trust Co raised its holdings in shares of Insulet by 90.9% during the second quarter. Diversified Trust Co now owns 9,130 shares of the medical instruments supplier's stock worth $1,842,000 after purchasing an additional 4,348 shares during the period. Natixis acquired a new position in shares of Insulet in the 1st quarter valued at about $3,610,000. Intech Investment Management LLC boosted its holdings in shares of Insulet by 113.8% in the 1st quarter. Intech Investment Management LLC now owns 6,649 shares of the medical instruments supplier's stock valued at $1,140,000 after buying an additional 3,539 shares during the period. Finally, Seven Eight Capital LP bought a new stake in shares of Insulet during the 1st quarter valued at about $1,418,000.

Analyst Ratings Changes

A number of brokerages have commented on PODD. Sanford C. Bernstein assumed coverage on Insulet in a research note on Wednesday, November 6th. They issued an "outperform" rating and a $300.00 target price for the company. Raymond James boosted their price objective on Insulet from $213.00 to $260.00 and gave the company an "outperform" rating in a research report on Monday, October 14th. UBS Group increased their target price on Insulet from $211.00 to $223.00 and gave the stock a "neutral" rating in a research report on Friday, August 9th. Morgan Stanley boosted their price target on shares of Insulet from $234.00 to $317.00 and gave the company an "overweight" rating in a report on Monday, November 11th. Finally, Citigroup increased their price objective on shares of Insulet from $250.00 to $275.00 and gave the stock a "buy" rating in a report on Tuesday, October 1st. Three equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat.com, Insulet presently has an average rating of "Moderate Buy" and a consensus target price of $253.27.

Insulet Price Performance

Shares of PODD traded up $1.31 during midday trading on Tuesday, reaching $261.99. The stock had a trading volume of 437,619 shares, compared to its average volume of 778,540. The firm's 50 day moving average price is $238.60 and its 200-day moving average price is $208.60. Insulet Co. has a 52 week low of $160.19 and a 52 week high of $279.40. The company has a market capitalization of $18.38 billion, a P/E ratio of 44.86, a P/E/G ratio of 3.98 and a beta of 1.22. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.